Cancer cell lines show regional losses across the Y chromosome
Researchers examined genome data from 160 male-derived cancer cell lines and found that Y-chromosome loss was not always complete: some gene-rich regions were deleted while others remained. The University of Arizona report and DCMedical cover the same finding. The peer-reviewed paper appeared on September 28. Cell-line associations do not establish that losing particular Y genes causes tumor growth in patients or that a proposed treatment would work.
Science··Evening
Gene-rich Y regions erode unevenly
A study of 160 male-derived cancer cell lines found that parts of the Y chromosome can disappear while other regions remain. The losses recurred in gene-rich stretches, so recording the chromosome as simply present or absent would miss differences among the cells. Researchers used genome sequencing and gene-expression data to examine that pattern. An independent medical news account described the same selective, regional losses and their links to cellular processes involved in tumor growth and stress responses.[1], [2]
Cell lines reveal a spectrum of loss
The team expressed the extent of Y erosion on a continuous scale instead of dividing samples into two groups. It identified 24 protein-coding Y-linked genes that were repeatedly lost. Loss of 15 of those genes also appeared in at least one of two external data sets, including data from bladder tumors and a panel spanning several cancer types. Genomes from healthy men did not show the same pattern. Those checks strengthen the observation that the losses arise in cancer cells, although they do not make every affected gene a proven driver of disease.[1]
Patient effects remain untested
The researchers also associated retained or missing Y-linked genes with changes in cell activity. The analysis was designed around laboratory cell lines, where background from normal cells is less likely to obscure the signal than in mixed tumor samples. That choice makes the regional pattern easier to map but limits what can be concluded about patients. The study does not establish that any one deletion causes a tumor to grow, nor does it test a therapy. Work in patient tumors and functional experiments would be needed before this map could guide care.[1]
